Ontario Mental Health Foundation Report issue

Academic/Hospital Phase 2 Phase 4
Founded: Toronto Canada (1962)

Organization Overview

First Clinical Trial
2001
NCT00745017
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 4 Trials (1)

citalopram (celexa) (2 trials)

Drugs in Phase 2 Trials (4)

methylphenidate (ritalin) (1 trial)

paroxetine (paxil) (2 trials)

sertraline (zoloft) (2 trials)

venlafaxine (effexor) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Binge-Eating Disorder (Phase 2)

Brain Injuries (Phase 4)

Brain Injuries, Traumatic (Phase 4)

Bulimia (Phase 2)

Depression (Phase 4)

Depressive Disorder (Phase 4)

Depressive Disorder, Major (Phase 2)

Feeding and Eating Disorders (Phase 2)

Wounds and Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 5